Novo Nordisk hits back at copycat drugs

Markets move fast. Get the insights you need in 10 minutes with Barclays Brief, a podcast from Barclays Investment Bank. Each week, our experts analyze market themes, helping you anticipate what's next. Listen to Barclays Brief, wherever you get your podcasts. Good morning from the Financial Times. Today is Tuesday, February 10th, and this is your FT News briefing.

Looks like the political turmoil in the UK has mellowed out, and Novo Nordisk is hitting back at copycat drugs. Plus, is American bank deposit investment? still strong enough. The Silicon Valley Bank failure was the first one to really take place in a fully digital era. And that meant that money could just move so much faster than it ever had before. I'm Sonia Hudson and here's the news you need to start your day.

UK government bonds went on a wild ride yesterday. Yields on the tenure jumped almost a tenth of a percentage point in the morning. Guilt investors were worried about more political fallout for Prime Minister Keir Starmer. He's come under fire for appointing Peter Mandelson as U.S. Ambassador, even though he knew about Mandelson's ongoing relationship with Jeffrey Epstein. On Monday morning, Scottish Labour leader Anna Sarwa called for Starmer to step down.

Investors worried that Starmer's potential downfall could lead to a rise in borrowing under a new prime minister. But his cabinet members swooped in and voiced their support for him. That seemed to calm traders and Gilt recovered some of their earlier losses. Several Labor MPs told the FT that Starmer's position is safe for now, but local elections in May will be a big test for him.

Novo Nordisk is suing to stop a U.S. telehealth company from selling copycat versions of its weight loss drug. The move escalates an industry-wide battle over obesity medications. And it comes as Novo is trying to reassure its investors. The Danish company's share price has fallen about fifteen percent over the past week, but it bounced back a little yesterday after the lawsuit news broke.

Here to tell us more is the FT's US pharmaceutical correspondent Patrick Temple West. Hey Patrick. Hello, Sonia. So tell me about this lawsuit that Novo filed yesterday. Sure. On Monday morning, Novo Nordisk sued this company called Him's and Hers, alleging patent infringement. that Hims and Hers is essentially selling copycat in their words, weight loss drugs in the US here, which violates Novonordisk's patents for Ozempic and Wagovie.

This has been simmering for a few months. Novo has never loved the fact that HIMS is offering is selling these drugs in the U.S. but It didn't really catch fire with the company until last week. When him's and hers just came out of the blue and said, We're going to offer a weight loss pill that is directly in competition with Novo's brand new weight loss pill. So him's share price fell sixteen percent yesterday. How has the company responded to the lawsuit?

Hims gave us a statement attacking Novo Nordis, calling it a Danish company, going after Americans who are trying to get weight loss drugs. him's backed down over the weekend and said it is no longer going to sell the weight loss pill that sparked this whole fight, but the horses are are are out of the barn at this point and Novo has has taken them to court. So we'll see where this fight goes.

And this lawsuit is coming on the heels of some disappointing earnings results and forecasts from Novo, right? So both companies are suffering um in the past year or so. Novo Nordisk, due to some pricing pressure in the US and significant competition from its top rival in weight loss. Eli Lilly. Last week it warned that its net sales would fall by as much as thirteen percent this year, which was not a good thing.

Worse than expected than than most analysts and investors were hoping for from the company. Novo's shares are down again and have dropped by more than fifty percent in the last year. Wow, that's incredible, especially given that Novo used to be Europe's most valuable company. Why is the company struggling so much? Part of it is Novo has significant competition from its only other rival in weight loss, Eli Lilly. Eli Lilly just seems to have a better sales apparatus.

Novo Nordisk has um come under pressure from President Donald Trump. Novo and and Lily did as well. They agreed to pricing deals with Trump late last year that dropped the price of Novo's weight loss drugs in the U.S. The company has been uh somewhat struggling in other areas. Novo Nordisk in November of last year announced that one of its um Alzheimer's trials failed to slow progression of the disease. So that has just been a good thing.

Added pressure on the company, added pain to the company, and really forced it to prioritize the weight loss space to keep its its revenues going. Patrick Temple West is the FT's US pharmaceutical correspondent. Thanks, Patrick. Thanks, Sonia.

The head of France's central bank, Francois Villeroy Degalot, is stepping down early. He made the announcement yesterday and said he was leaving the Bank of France to run a charitable foundation. The timing of this move is notable. It means that President Emmanuel Macron can name a replacement before the presidential election next spring. Macron can't run again, and the far right is pulling way ahead of the left and center.

One analyst told the FT that Villeroy Desgalo's decision could be based on the fact that, quote, monetary policy independence seems to be an issue for a growing number of political leaders. Villeroy Degalot though said he was departing for personal reasons. He'll leave his post in early June.

How much does it cost to end bank runs in the US? Lawmakers are grappling with this question. They're considering a proposal to reform the country's deposit insurance program. This comes about three years after customers pulled tens of billions of dollars out of Silicon Valley Bank in just a matter of hours, and that led to its collapse. The bill has divided Washington and the banking industry. Here to tell us more is the FT's U.S. banking editor, Josh Franklin. Hey, Josh. Hi there.

So tell me about this bill to expand the deposit insurance program. So just to take a step back, right now all deposits in the United States at a bank, up to two hundred and fifty thousand dollars are insured, guaranteed by the US government. What this proposal would change is For operating accounts, so for businesses that aren't earning any interest, it would lift the um insurance threshold from two hundred fifty thousand dollars to ten million dollars.

Uh but crucially, and just to make it a little bit more uh confusing, uh that increased insurance threshold would apply to every bank in the United States except for the eight largest banks. So think of the JP Morgan's the Bank of America's the Wells Fargo Citigroups of the W And what's the argument for doing this? So the argument is that these biggest banks, and these eight banks, they're, you know, to use a kind of common phrase, they're judged too big to fail.

And the view is that because they have these designation, they benefit from almost an implicit government guarantee. So customers in especially in a time of crisis, are s feel safer keeping their money with these big banks, and that puts the smaller banks at a competitive disadvantage. Can you just give us some background on bank runs in the US and why the SVB collapse was a big enough deal to prompt this kind of reform?

One important thing to say is failures and bank runs are still very rare in the United States. But what was so notable about the the SVB failure, which at the time was the second largest largest bank failure in US history It was that it was the first one to really take place in a fully digital era.

And that meant that money could just move so much faster than it ever had before. And so in a world where that can happen, lawmakers and industry groups really did feel like this this deposit insurance wasn't fit for the digital era. Yeah, going back to this bill to expand deposit insurance, who is opposed to it? So not big surprise that the large banks are not in favor of this bill. They feel like it would create a two tier insurance system that would be confusing to consumers.

And they argue that it would penalize their customers for actually being with a big bank. But then also you do get some uh some smaller bank executives who feel like, you know, there are adequate tools right now that that would allow them to compete. against the big banks and just kind of by improving their offering, they can still compete adequately. What about among politicians in Washington?

In Washington it's one of those kind of slightly funky issues where there's both bipartisan support and bipartisan opposition to this bill. Bipartisan support, you know, you're you're never an unpopular politician in your home state if you're seen as being supportive.

of local banks um and small businesses. There is some concern about how you pay for this because right now deposit insurance in the United States, it's an insurance program where actually the industry pays in regular premiums to a fund What this proposal would do is obviously increase the amount of deposits that will be covered by deposit insurance, and so therefore there would be more money needed to be paid into it. And the argument from some small banks is that

The large banks have already been benefiting, profiting from this implicit government guarantee, so they should be the ones that have to pay for any increased costs, even if they're not going to see any increase in their insurance coverage. And as you can imagine, the large banks are not exactly thrilled with that idea. Do you think there's enough political willpower to get reform like this passed? You know, where do you see this issue going from here?

I think there definitely is political will for something to happen. I think now it's a question of, you know, bandwidth of, you know, what Congress can actually get to, and also just finding a solution that um everyone is is on board with. So I think there's a very decent chance that this is something that, you know, you do see meaningful progress on this year, but I don't want to be a hostage to fortune by making too strong a prediction about what's gonna happen to Donald Trump's DC.

Josh Franklin is the FT's US banking editor. Thanks, Josh. Thanks very much. You can read more on all these stories for free when you click the links in our show notes. This has been your daily FT News Briefing. Check back tomorrow for the latest business news. It's not difficult to find out who. It's easy to know what and where. But why is harder? Why takes patience, intelligence, determination.

Why takes over 700 of the best journalists in the world united by a fearless drive to unearth the truth. Why is difficult and more important than ever before. For the why is Financial time.